Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. LFVN
LFVN logo

LFVN Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
4.810
Open
4.580
VWAP
4.72
Vol
172.46K
Mkt Cap
61.21M
Low
4.580
Amount
814.58K
EV/EBITDA(TTM)
4.07
Total Shares
12.80M
EV
48.28M
EV/OCF(TTM)
12.88
P/S(TTM)
0.28
LifeVantage Corporation is an activation company, which is engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and pro-biotics, skin and hair care products, and nootropics. The Company’s line of scientifically validated activators includes the flagship Protandim family of products, TrueScience Liquid Collagen, the newest MindBody GLP-1 System, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System , as well as AXIO nootropic energy drink mixes, the full TrueScience line of skin and hair care products, and Petandim, a pet supplement formulated to combat oxidative stress in dogs. It sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand and Singapore.
Show More

Events Timeline

(ET)
2026-04-16
17:20:00
LifeVantage Appoints Terrence Moorehead as New CEO
select
2026-03-10 (ET)
2026-03-10
16:40:00
LifeVantage Files $75M Mixed Securities Shelf
select
2026-02-04 (ET)
2026-02-04
16:40:00
LifeVantage CEO Steve Fife to Retire in April
select
2026-02-04
16:20:00
Company Cuts FY26 Revenue Outlook to $185M-$200M
select
2026-02-04
16:20:00
LifeVantage Q2 Revenue at $48.93M, Below Expectations
select
2026-01-07 (ET)
2026-01-07
16:30:00
LifeVantage Appoints Mike Edwards as Chief Technology Officer
select
2025-11-12 (ET)
2025-11-12
08:20:41
LifeVantage Reveals New In Vitro Study Findings for P84 Formula
select
2025-11-04 (ET)
2025-11-04
17:24:24
LifeVantage confirms FY26 EPS forecast of $1.00-$1.15, aligning with consensus of $1.01
select

News

seekingalpha
5.0
04-16seekingalpha
LifeVantage Appoints New CEO Terrence Moorehead Effective August 2026
  • Executive Appointment: LifeVantage has appointed Terrence Moorehead as the new President and CEO, effective August 5, 2026, marking a significant leadership change aimed at driving future growth and innovation within the company.
  • Succession Plan: Moorehead will succeed Steve Fife, who is set to retire on April 30, with Director Michael Beindorff serving as interim CEO during the transition, ensuring stable operations throughout this period.
  • Board Membership: New CEO Moorehead will also join the LifeVantage board, a move that not only strengthens corporate governance but also provides robust leadership support for future strategic decisions.
  • Market Reaction: This executive change may impact investor confidence, particularly as the company faces market challenges from GLP-1 hormone drugs and the integration of LoveBiome, with the future leadership direction likely to have profound implications for company performance.
Newsfilter
5.0
04-16Newsfilter
LifeVantage Appoints New CEO Terrence Moorehead
  • New CEO Appointment: LifeVantage has appointed Terrence Moorehead as the new President and CEO, effective August 5, 2026, bringing over 25 years of leadership experience that is expected to revitalize the brand and accelerate customer growth.
  • Retirement of Former CEO: Current CEO Steve Fife will retire on April 30, 2026, with Moorehead's appointment aimed at ensuring leadership stability during the transition, as Fife has significantly contributed to the company's transformation and financial health over the past nine years.
  • Transition Leadership Team: Prior to Moorehead's start, the Board has appointed Michael Beindorff as Interim CEO to ensure continuity, with the interim team comprising experienced executives capable of effectively managing the company's operations during this period.
  • Strategic Growth Potential: Moorehead expressed that LifeVantage's science-backed products and passionate consultant community create a strong foundation for future growth, with expectations to further enhance brand positioning and drive sustainable growth to deliver shareholder value.
moomoo
5.0
04-16moomoo
LIFEVANTAGE CORP NAMES TERRENCE MOOREHEAD PRESIDENT AND CEO STARTING AUGUST 5, 2026
  • Leadership Change: LifeVantage Corporation has appointed Terrence Moorehead as the new President and CEO.
  • Effective Date: The appointment will take effect on August 5, 2026.
Benzinga
9.5
02-05Benzinga
Align Technology Reports Strong Q4 Earnings Beat
  • Earnings Beat: Align Technology reported Q4 earnings of $3.29 per share, surpassing analyst expectations of $2.97, indicating a significant improvement in profitability and boosting market confidence in future growth.
  • Sales Growth: The company achieved quarterly sales of $1.047 billion, exceeding the consensus estimate of $1.033 billion, demonstrating robust performance amid strong market demand.
  • Stock Surge: Align's shares jumped 10.4% in pre-market trading to $178.13, reflecting a positive investor reaction to the financial results, which may attract more investor interest.
  • Increased Market Confidence: This earnings beat not only enhances Align's market image but also potentially supports its future investment and expansion plans, further solidifying its leadership position in the industry.
seekingalpha
9.5
02-05seekingalpha
LifeVantage Q2 2026 Earnings Call Insights
  • Revenue Decline: LifeVantage reported net revenue of $48.9 million for Q2, a 27.8% year-over-year decrease primarily driven by declining sales of the MindBody GLP-1 system, highlighting intensified competition in the natural GLP-1 market that adversely affected overall performance.
  • Inventory Management Strategy: The company recognized a $2.4 million reserve against a portion of its GLP-1 inventory to mitigate risks from overestimated demand, while also evaluating cost reduction opportunities to ensure sustained profitability amidst competitive pressures.
  • Shareholder Return Plan: LifeVantage announced a new $60 million share repurchase authorization, reinforcing its commitment to shareholders, having returned over $20 million through dividends and share repurchases in the past six months.
  • Future Outlook: The CFO provided updated guidance indicating expected revenue in the range of $185 million to $200 million, reflecting positive expectations from LoveBiome integration and the potential impact of upcoming product launches.
NASDAQ.COM
2.0
02-04NASDAQ.COM
LifeVantage (LFVN) Q2 2026 Earnings Transcript
Wall Street analysts forecast LFVN stock price to rise
1 Analyst Rating
Wall Street analysts forecast LFVN stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
12.00
Averages
12.00
High
12.00
Current: 0.000
sliders
Low
12.00
Averages
12.00
High
12.00
Lake Street
Buy
downgrade
$12 -> $5
AI Analysis
2026-02-05
Reason
Lake Street
Price Target
$12 -> $5
AI Analysis
2026-02-05
downgrade
Buy
Reason
Lake Street lowered the firm's price target on LifeVantage to $5 from $12 and keeps a Buy rating on the shares after the company's second quarter results and updated guidance were weaker than expected. With shares trading off 25% after hours, the firm believes valuation has likely troughed and thinks "there is a path for the multiple to work higher over time" if the company can execute against its revised FY26 guidance, the analyst tells investors.
Lake Street
Ryan Meyers
Buy
downgrade
$30 -> $12
2025-11-05
Reason
Lake Street
Ryan Meyers
Price Target
$30 -> $12
2025-11-05
downgrade
Buy
Reason
Lake Street analyst Ryan Meyers lowered the firm's price target on LifeVantage to $12 from $30 and keeps a Buy rating on the shares after Q1 results that reflected a seasonally soft period and tougher year-over-year comparisons. The analyst, while taking over coverage, is trimming the firm's price target to reflect a revised revenue outlook and slightly lower valuation multiple.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for LFVN
Unlock Now

Valuation Metrics

The current forward P/E ratio for LifeVantage Corp (LFVN.O) is 37.45, compared to its 5-year average forward P/E of 11.89. For a more detailed relative valuation and DCF analysis to assess LifeVantage Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
11.89
Current PE
37.45
Overvalued PE
21.07
Undervalued PE
2.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
4.81
Current EV/EBITDA
15.64
Overvalued EV/EBITDA
7.23
Undervalued EV/EBITDA
2.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.42
Current PS
0.31
Overvalued PS
0.64
Undervalued PS
0.20

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

buyout soon
Intellectia · 22 candidates
Industry: Biotechnology & Medical Research, PharmaceuticalsRegion: USCurrent Ratio: >= 1.20List Exchange: XNYS, XNAS, XASEPs Ratio: <= 4.00Year Price Change Pct: <= $-40.00
Ticker
Name
Market Cap$
top bottom
MBIO logo
MBIO
Mustang Bio Inc
5.30M
ENVB logo
ENVB
Enveric Biosciences Inc
3.71M
LFVN logo
LFVN
LifeVantage Corp
53.14M
PRGO logo
PRGO
Perrigo Company PLC
1.49B
YCBD logo
YCBD
cbdMD Inc
7.14M
INM logo
INM
InMed Pharmaceuticals Inc
2.37M
low float medical tech stock
Intellectia · 68 candidates
Market Cap: 50.00M - 5.00BSector: Healthcare, Healthcare Services & Equipment, Pharmaceuticals & Medical ResearchRegion: USPrice: $1.00 - $50.00Beta: ModerateRisk, HighRisk, LowRisk, NegativeBetaList Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 300,000Floating Shares: <= 20,000,000
Ticker
Name
Market Cap$
top bottom
XLO logo
XLO
Xilio Therapeutics Inc
50.19M
LPCN logo
LPCN
Lipocine Inc
54.02M
LFVN logo
LFVN
LifeVantage Corp
54.88M
CLNN logo
CLNN
Clene Inc
63.49M
OM logo
OM
Outset Medical Inc
64.46M
ACET logo
ACET
Adicet Bio Inc
64.58M
create swing trade setup
Intellectia · 358 candidates
Price: $1.00 - $5.00List Exchange: XNAS, XNYS, XASEMoving Average Relationship: PriceAboveMA20, PriceBelowMA5, PriceBelowMA10Week Price Change Pct: $-10.00 - $10.00Macd: bullish, positive
Ticker
Name
Market Cap$
top bottom
TCRT logo
TCRT
Alaunos Therapeutics Inc
7.60M
OSTX logo
OSTX
OS Therapies Inc
53.17M
NNOX logo
NNOX
Nano-X Imaging Ltd
169.34M
FLNT logo
FLNT
Fluent Inc
107.58M
LXRX logo
LXRX
Lexicon Pharmaceuticals Inc
685.30M
MRT logo
MRT
Marti Technologies Inc
175.91M
best way to make 10 to 100
Intellectia · 45 candidates
Market Cap: 10.00M - 100.00MWeekly Average Turnover: >= 1,000,000Annual Revenue Yoy Growth: >= 0.0%
Ticker
Name
Market Cap$
top bottom
AMTX logo
AMTX
Aemetis Inc
98.64M
MIND logo
MIND
Mind Technology Inc
94.90M
HYFT logo
HYFT
MindWalk Holdings Corp
94.78M
SSTI logo
SSTI
SoundThinking Inc
93.71M
IROQ logo
IROQ
IF Bancorp Inc
91.20M
SYPR logo
SYPR
Sypris Solutions Inc
89.82M

Whales Holding LFVN

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is LifeVantage Corp (LFVN) stock price today?

The current price of LFVN is 4.78 USD — it has increased 4.6

What is LifeVantage Corp (LFVN)'s business?

LifeVantage Corporation is an activation company, which is engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and pro-biotics, skin and hair care products, and nootropics. The Company’s line of scientifically validated activators includes the flagship Protandim family of products, TrueScience Liquid Collagen, the newest MindBody GLP-1 System, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System , as well as AXIO nootropic energy drink mixes, the full TrueScience line of skin and hair care products, and Petandim, a pet supplement formulated to combat oxidative stress in dogs. It sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand and Singapore.

What is the price predicton of LFVN Stock?

Wall Street analysts forecast LFVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFVN is12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is LifeVantage Corp (LFVN)'s revenue for the last quarter?

LifeVantage Corp revenue for the last quarter amounts to 48.93M USD, decreased -27.79

What is LifeVantage Corp (LFVN)'s earnings per share (EPS) for the last quarter?

LifeVantage Corp. EPS for the last quarter amounts to 0.02 USD, decreased -89.47

How many employees does LifeVantage Corp (LFVN). have?

LifeVantage Corp (LFVN) has 232 emplpoyees as of April 19 2026.

What is LifeVantage Corp (LFVN) market cap?

Today LFVN has the market capitalization of 61.21M USD.